Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression (BDep) have a distinct lag of onset that can generate great distress and impairment in patients. Furthermore, as demonstrated by several real-world effectiveness trials, their efficacy is limited. All approved antidepressant medications for MDD primarily act through monoaminergic mechanisms, agonists or antagonists with varying affinities for serotonin, norepinephrine and dopamine. The glutamate system has received much attention in recent years as an avenue for developing novel therapeutics. A single subanesthetic dose infusion of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has been shown to have rapid and potent antidepressant effects in treatment-resistant MDD and BDep. In a reverse translational framework, ketamine’s clinical efficacy has inspired many preclinical studies to explore glutamatergic mechanisms of antidepressant action. These studies have revealed enhanced synaptic plasticity/synaptogenesis via numerous molecular and cellular mechanisms: release of local translational inhibition of brain-derived neurotrophic factor and secretion from dendritic spines, mammalian target of rapamycin activation and glycogen synthase kinase-3 inhibition. Current efforts are focused on extending ketamine’s antidepressant efficacy, uncovering the neurobiological mechanisms responsible for ketamine’s antidepressant activity in biologically enriched subgroups, and identifying treatment response biomarkers to personalize antidepressant selection. Other NMDA receptor antagonists have been studied both preclinically and clinically, which have revealed relatively modest antidepressant effects compared with ketamine but potentially other favorable characteristics, for example, decreased dissociative or psychotomimetic effects; therefore, there is great interest in developing novel glutamatergic antidepressants with greater target specificity and/or decreased adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postsynaptic activity triggers BDNF release and TrkB receptor activation, which in turn engages mechanistic target of rapamycin complex 1 (mTORC1) dependent translational programs supporting dendritic spine growth and synaptic strengthening [20,42,48,49,50].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The result is a brief but robust glutamate surge that drives enhanced α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) throughput and calcium influx, including through calcium permeable AMPA channels [20,42,47].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At subanesthetic doses, ketamine preferentially antagonizes N-methyl-D-aspartate receptors (NMDARs) on fast spiking GABAergic interneurons, releasing pyramidal neurons from inhibitory control [42,43,44,45,46].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [42]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258 · cited 2×
“In the only published study of patients who were acutely suicidal and encountered in an emergency setting, open-label intravenous ketamine (0.2 mg/kg intravenous push over 1–2 min) had both acute antidepressant and antisuicidal effects in 14 patients with depression [Larkin and Beautrais, 2011].”
BackgroundInfluentialRetractedMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 1×
“In preclinical models of despair, ketamine activates mammalian target of rapamycin (mTOR), which is a critical hub of cellular growth and proliferation [Hay and Sonenberg, 2004].”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“HDRS scores significantly decreased with ketamine compared with placebo within 240 min and were maintained for at least 3 days [Berman et al. 2000].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“Ketamine increased mTOR phosphorylation and other downstream molecular targets critical for transcriptional activation within 1 hour of administration [Li et al. 2010].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“However, because ketamine inhibits eEF-2K functioning, eEF-2 activity predominates, which results in greater local BDNF translation in dendritic spines [Autry et al. 2011].”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Preclinical studies The prevailing cellular and molecular hypotheses for ketamine’s mechanism of action is that NMDA receptor blockade on cortical γ-aminobutyric acid(GABA)ergic interneurons releases the tonic inhibition on major output neurons, for example, cortical pyramidal cells [Moghaddam et al. 1997].”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“Over the course of the last 15 years, ketamine’s rapid and robust antidepressant properties in MDD and BDep have been labeled by some leaders in the field as ‘arguably the most important discovery (in depression research) in half a century’ [Duman and Aghajanian, 2012].”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128 · cited 2×
“An intriguing difference between the mechanisms of ketamine and monoaminergic antidepressant therapies is ketamine and other NMDA receptor antagonists’ rapid (within 24 h) neuroplastic effects, increased synaptic protein expression, dendritic spine morphogenesis (filopodia to mushroom shaped spines) and excitatory pos…”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationLi, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082 · cited 1×
“In an unpredictable foot shock paradigm, the NR2B antagonist Ro 25-6981 had antidepressantlike behavioral effects [Li et al. 2011].”
BackgroundDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Self-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Self-citationSignaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537 · cited 1×
“An intriguing difference between the mechanisms of ketamine and monoaminergic antidepressant therapies is ketamine and other NMDA receptor antagonists’ rapid (within 24 h) neuroplastic effects, increased synaptic protein expression, dendritic spine morphogenesis (filopodia to mushroom shaped spines) and excitatory pos…”
BackgroundMiniature synaptic events maintain dendritic spines via AMPA receptor activation
McKinney, R. A., Capogna, M., Dürr, R., Gähwiler, B. H., & Thompson, A. S. M. (1999) · Nature Neuroscience · doi:10.1038/4548 · Cited by 523
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520 · cited 2×
“Safety and tolerability As mentioned, ketamine has been used safely and effectively as a dissociative anesthetic since its introduction in the 1960s [Domino, 2010].”
BackgroundPreskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 1×
“Intranasal Finally, in a randomized, double-blind, crossover, placebo-controlled trial, 20 patients with major depression were randomized to either intranasal ketamine (50 mg) or a saline solution with the primary outcome being depression change at 24 h [Lapidus et al. 2014].”
MethodPharmacology of Ketamine Isomers in Surgical Patients
White, P. F., Ham, J., Way, W. L., & Trevor, A. (1980) · Anesthesiology · doi:10.1097/00000542-198003000-00008 · Cited by 425
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Self-citationMorgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties
Han, K., Holder Jr, J. L., Schaaf, C. P., Lu, H., Chen, H., Kang, H., Tang, J., Wu, Z., Hao, S., Cheung, S. W., et al. (2013) · Nature · doi:10.1038/nature12630 · Cited by 353
Price, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., Soleimani, L., Charney, D. S., Foulkes, A. L., & Mathew, S. J. (2014) · Depression and Anxiety · doi:10.1002/da.22253 · Cited by 345
Overview of glutamatergic neurotransmission in the nervous system
Niciu, M. J., Kelmendi, B., & Sanacora, G. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.008 · Cited by 329 · cited 1×
“The glutamate system Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system [Niciu et al. 2012] and, at physiological levels, is essential for dendritic development and neuronal growth [McKinney et al.”
BackgroundSelf-citationIbrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Self-citationMathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., & Charney, D. S. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 294
Beurel, E., Song, L., & Jope, R. S. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.47 · Cited by 288
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Self-citationDo the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 2×
“In our combined sample, dissociative side effects at the end of the 40 minute infusion predicted eventual antidepressant improvement at both 230 minutes and 1 week afterwards; hemodynamic and psychotomimetic side effects, however, did not correlate with ketamine’s antidepressant efficacy at any of the aforementioned t…”
BackgroundSelf-citationLally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.105 · Cited by 271 · cited 1×
“A subsequent study in the same sample analyzed ketamine’s antianhedonic effects and rMRGlu, which, in addition to a reduction in anhedonia independent of depression improvement, reported a correlation between ketamine’s antianhedonic effects and increased dorsal anterior cingulate cortex and putamen rMRGlu [Lally et a…”
ResultSelf-citationLiu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256 · cited 1×
“Finally, GSK-3 inhibition by lithium and a selective GSK-3 inhibitor (SB 216763) potentiates the antidepressant, synaptogenic and electrophysiological effects of subthreshold dose (1 mg/kg) ketamine, for example, mTOR activation, increased excitatory postsynaptic currents and dendritic spine morphogenesis [Liu et al.…”
BackgroundZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“AZD6765 had lower response rates, lower remission rates, and a shorter duration of effect [Zarate et al. 2013].”
BackgroundSelf-citationHaile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
Ketamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238
Sanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236
Gideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
Wan, L.-B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., Foulkes, A., Mathew, S. J., Charney, D. S., & Murrough, J. W. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08852 · Cited by 231
Ibrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220
Self-citationSerial infusions of low-dose ketamine for major depression
Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., Ritter, M. J., Schak, K. M., Sola, C. L., Hanson, A. J., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478283 · Cited by 217
Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213
Self-citationValentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., Krystal, J. H., & Sanacora, G. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.10.009 · Cited by 204
(2013) · PubMed · Cited by 192
Phelps, L. E., Brutsche, N., Moral, J. R., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.029 · Cited by 189
Self-citationMorgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02394.x · Cited by 187
A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177
Diamond, P. R., Farmery, A. D., Atkinson, S., Haldar, J., Williams, N., Cowen, P. J., Geddes, J. R., & McShane, R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114527361 · Cited by 176
Koike, H., & Chaki, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.065 · Cited by 175 · cited 2×
“2013; Koike and Chaki, 2014] and the activation of second messenger/signal transduction cascades [Niciu et al.”
BackgroundIrwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Self-citationNext-Generation Treatments for Mental Disorders
Insel, T. R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004873 · Cited by 164 · cited 1×
“Furthermore, while other areas of medicine have seen significant reductions in morbidity and mortality, the same cannot be said for mental illnesses and suicidality [Insel, 2012].”
BackgroundNiciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 161
Self-citationMachado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Self-citationMullard, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3946 · Cited by 154 · cited 1×
“2012 was a record year for the previous half decade in terms of new drug approvals; yet, the majority (33% of the list of 39 new drugs) had primary efficacy in oncology whereas neuropsychiatric drugs accounted for just around 5% [Mullard, 2013].”
BackgroundLara, D. R., Bisol, L. W., & Munari, L. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 138 · cited 2×
“In 27 outpatients with current unipolar and bipolar depression, variable administration (every 2–7 days of add-on escalating (but still subanesthetic) dose sublingual ketamine had antidepressant efficacy in 20 patients (77% of sample) [Lara et al. 2013].”
BackgroundChowdhury, G. M. I., Behar, K. L., Cho, W., Thomas, M. A., Rothman, D. L., & Sanacora, G. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.006 · Cited by 125
Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Abdallah, C. G., Fasula, M., Kelmendi, B., Sanacora, G., & Ostroff, R. (2012) · The Journal of ECT · doi:10.1097/yct.0b013e31824f8296 · Cited by 123
Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care
Irwin, S. A., & Iglewicz, A. (2010) · Journal of Palliative Medicine · doi:10.1089/jpm.2010.9808 · Cited by 123 · cited 5×
“While more work is needed to further explore repeated dosing, other studies have examined alternative methods of delivery: oral [Irwin and Iglewicz, 2010; Paslakis et al.”
BackgroundInfluentialRéus, G. Z., Stringari, R. B., Kirsch, T. R., Fries, G. R., Kapczinski, F. P., Roesler, R., & Quevedo, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.11.013 · Cited by 119
Psychiatric safety of ketamine in psychopharmacology research
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117
Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine
Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., Slonena, E. E., Vande Voort, J. L., Brutsche, N. E., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09049 · Cited by 111 · cited 1×
“2014b] [Clinical Trials identifier: NCT02122562] or dimensional anxious depression [Ionescu et al. 2014], to develop treatment response biomarkers and other surrogate endpoints for personalized antidepressant treatment selection.”
BackgroundSelf-citationMealing, G. A. R., Lanthorn, T. H., Murray, C. L., Small, D. L., & Morley, P. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37943-1 · Cited by 102
Järventausta, K., Chrapek, W., Kampman, O., Tuohimaa, K., Björkqvist, M., Häkkinen, H., Yli-Hankala, A., & Leinonen, E. (2013) · The Journal of ECT · doi:10.1097/yct.0b013e318283b7e9 · Cited by 97
Rybakowski, J. K., Permoda‐Osip, A., Skibinska, M., Adamski, R., & Bartkowska‐Sniatkowska, A. (2013) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2271 · Cited by 93
Quan, M., Zhang, N., Wang, Y.-Y., Zhang, T., & Yang, Z. R. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.026 · Cited by 92
Acute d-serine treatment produces antidepressant-like effects in rodents
Malkesman, O., Austin, D. R., Tragon, T., Wang, G., Rompala, G., Hamidi, A. B., Cui, Z., Young, W. S., Nakazawa, K., Zarate, C. A., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001386 · Cited by 92
Self-citationGhasemi, M., Raza, M., & Dehpour, A. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109104845 · Cited by 90
Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89
Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86
Self-citationAcute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine
Chilukuri, H., Reddy, N. P., Pathapati, R. M., Manu, A. N., Jollu, S., & Shaik, A. B. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.127258 · Cited by 86
Neural correlates of rapid antidepressant response to ketamine in bipolar disorder
Nugent, A. C., Diazgranados, N., Carlson, P. J., Ibrahim, L., Luckenbaugh, D. A., Brutsche, N., Herscovitch, P., Drevets, W. C., & Zarate, C. A. (2014) · Bipolar Disorders · doi:10.1111/bdi.12118 · Cited by 85 · cited 1×
“Next, 21 treatment-resistant patients with bipolar depression received [(18)-F]fluorodeoxyglucose positron emission tomography scans to assess the metabolic rate of glucose (rMRGlu) after both placebo and ketamine infusions [Nugent et al. 2014].”
MethodSelf-citationDose- and Exposure-Response to Ketamine in Depression
Glue, P., Gulati, A., Nedelec, M. L., & Duffull, S. B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.031 · Cited by 84
Larkin, G. L., Beautrais, A. L., Turelli, R. R., Sanacora, G., Powsner, S., Lippmann, M., & Krystal, J. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)73311-9 · Cited by 80
Hippocampal volume and the rapid antidepressant effect of ketamine
Abdallah, C. G., Salas, R., Jackowski, A., Baldwin, P., Sato, J. R., & Mathew, S. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114544776 · Cited by 78
Attentional bias to incentive stimuli in frequent ketamine users
Morgan, C. J. A., Rees, H., & Curran, H. V. (2008) · Psychological Medicine · doi:10.1017/s0033291707002450 · Cited by 76
Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M. P., Laje, G., Zarate, C., Barbas, C., & Wainer, I. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12494 · Cited by 71
Self-citationLong-Term Maintenance With Intramuscular Ketamine for Treatment-Resistant Bipolar II Depression
Cusin, C., Hilton, G. Q., Nierenberg, A. A., & D, M. F. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12020219 · Cited by 69 · cited 1×
“2013; De Gioannis and De Leo, 2014], intramuscular [Cusin et al. 2012], sublingual [Lara et al.”
BackgroundPaslakis, G., Gilles, M., Meyer-Lindenberg, A., & Deuschle, M. (2010) · Pharmacopsychiatry · doi:10.1055/s-0029-1237375 · Cited by 66
Anand, A., Gunn, A. D., Barkay, G., Karne, H. S., Nurnberger, J. I., Mathew, S. J., & Ghosh, S. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00971.x · Cited by 65
On the safety and benefits of repeated intravenous injections of ketamine for depression.
Blier, P., Zigman, D., & Blier, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.039 · Cited by 64 · cited 1×
“Finally, there is a case report of a 44-year-old patient with TRD who received more than 40 ketamine infusions over several months [Blier et al. 2012].”
BackgroundKetamine regulates the presynaptic release machinery in the hippocampus
Müller, H. K., Wegener, G., Liebenberg, N., Zarate, C. A., Popoli, M., & Elfving, B. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.008 · Cited by 61
Self-citationLineberry, T. W., & O’Connor, S. S. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.07.002 · Cited by 56 · cited 1×
“In the first half of 2012, depression and suicide were brought to the forefront of public attention as the number of US Army deaths from suicide outpaced the number of combat casualties [Lineberry and O’Connor, 2012].”
BackgroundNiciu, M. J., Grunschel, B. D., Corlett, P. R., Pittenger, C., & Bloch, M. H. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113486718 · Cited by 52
Self-citationZhou, W., Dong, L., Wang, N., Shi, J.-Y., Yang, J.-J., Zuo, Z.-Y., & Zhou, Z.-Q. (2014) · Neuroimmunomodulation · doi:10.1159/000356517 · Cited by 49
Oral ketamine augmentation for chronic suicidality in treatment-resistant depression
De Gioannis, A., & De Leo, D. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414520754 · Cited by 46
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
Niciu, M. J., Mathews, D. C., Nugent, A. C., Ionescu, D. F., Furey, M. L., Richards, E. M., Machado-Vieira, R., & Zarate, C. A. (2014) · Depression and Anxiety · doi:10.1002/da.22224 · Cited by 45
Self-citationNiciu, M. J., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A. (2013) · CNS Spectrums · doi:10.1017/s1092852913000059 · Cited by 43
Self-citationAndreasen, J. T., Gynther, M., Rygaard, A., Bøgelund, T., Nielsen, S. D., Clausen, R. P., Mogensen, J., & Pickering, D. S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.04.045 · Cited by 42
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.038 · Cited by 39
Self-citationVitamin B12 Level may be Related to the Efficacy of Single Ketamine Infusion in Bipolar Depression
Permoda-Osip, A., Dorszewska, J., Bartkowska-Sniatkowska, A., Chlopocka-Wozniak, M., & Rybakowski, J. (2013) · Pharmacopsychiatry · doi:10.1055/s-0033-1349861 · Cited by 37
Kollmar, R., Markovic, K., Thürauf, N., Schmitt, H., & Kornhuber, J. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701787628 · Cited by 37
Intramuscular ketamine in acute depression: A report on two cases
Harihar, C., Dasari, P., & Srinivas, J. (2013) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.111461 · Cited by 36 · cited 1×
“A follow-up case series in two Indian patients with depression also reported rapid antidepressant efficacy to intramuscular ketamine [Harihar et al. 2013].”
BackgroundFactors connected with efficacy of single ketamine infusion in bipolar depression
Permoda-Osip, A., Skibińska, M., Bartkowska-Śniatkowska, A., Kliwicki, S., Chłopocka-Woźniak, M., & Rybakowski, J. (2014) · Psychiatria Polska · doi:10.12740/pp/21175 · Cited by 34
Ortiz, R., Niciu, M. J., Lukkahati, N., Saligan, L. N., Nugent, A. C., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.015 · Cited by 32
Self-citationMorgan, C. J. A., Duffin, S. R., Hunt, S., Monaghan, L., Mason, O. J., & Curran, H. V. (2012) · Pharmacopsychiatry · doi:10.1055/s-0032-1306310 · Cited by 28
Homocysteine and cognitive functions in bipolar depression
Permoda‐Osip, A., Kisielewski, J., Dorszewska, J., & RYBAKOWSKI, J. K. (2014) · Psychiatria Polska · doi:10.12740/pp/31394 · Cited by 27
Lundin, N. B., Niciu, M. J., Luckenbaugh, D. A., Ionescu, D., Richards, E. M., Voort, J. V., Brutsché, N. E., Machado‐Vieira, R., & Zarate, C. A. (2014) · Pharmacopsychiatry · doi:10.1055/s-0034-1377042 · Cited by 18
Self-citation
Research works printed but not linked: 1
- 90. Sanacora G., Johnson M., Khan A., Atkinson S., Risenberg R., Schronen J., et al. (2014a) Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebo-controlled study (PURSUIT). Poster presented on 18 June at the 2014 American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, FL. [[Google Scholar](https://scholar.google.com/scholar_lookup?Sanacora%20G.,%20Johnson%20M.,%20Khan%20A.,%20Atkinson%20S.,%20Risenberg%20R.,%20Schronen%20J.,%20et%20al.%20(2014a)%20Adjunctive%20lanicemine%20(AZD6765)%20in%20patients%20with%20major%20depressive%20disorder%20and%20a%20history%20of%20inadequate%20response%20to%20antidepressants:%20primary%20results%20from%20a%20randomized,%20placebo-controlled%20study%20(PURSUIT).%20Poster%20presented%20on%2018%20June%20at%20the%202014%20American%20Society%20of%20Clinical%20Psychopharmacology%20Annual%20Meeting%20in%20Hollywood,%20FL.)]
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
The neurobiology of depression: An integrated view
Dean, J., & Keshavan, M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.025 · Cited by 765
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Self-citationThe orbitofrontal cortex and emotion in health and disease, including depression
Rolls, E. T. (2019) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.09.021 · Cited by 329
“Treatments that can reduce depression such as a single dose of ketamine (Iadarola et al., 2015) may act in part by quashing the attractor state in the lateral orbitofrontal cortex/ventrolateral prefrontal cortex at least temporarily (though there is also evidence that ketamine’s effect on depression may be related to…”
Nutrition and behavioral health disorders: depression and anxiety
Kris-Etherton, P. M., Petersen, K. S., Hibbeln, J. R., Hurley, D., Kolick, V., Peoples, S., Rodriguez, N., & Woodward-Lopez, G. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuaa025 · Cited by 318
“overactivates the glutamatergic receptor (N-methyl-Daspartate), and is implicated in depression.(75) Higher intake of vitamin B12 and folate is associated with lower risk of depression in epidemiological studies,(76,77) although it is unclear whether vitamin B12 and folate adequacy prevents the onset of depression.”
Background
Metadata
- Authors
- Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- National Institutes of Health/National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch, Bethesda, MD, USA
- Venue
- Therapeutic Advances in Chronic Disease
- Publisher
- SAGE Publications
- Published
- 2015-04-13
- Volume
- 6
- Issue
- 3
- Pages
- 97-114
- ISSN
- 2040-6223 (ISSN-L)
- 2040-6231
- PMC
- PMC4416968
- OpenAlex
- W2055661286
- Cited by
- 201
- References
- 104
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 10 · 2022: 16 · 2021: 20 · 2020: 16 · 2019: 24 · 2018: 20 · 2017: 16 · 2016: 35 · 2015: 16
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-05-17)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Chronic Disease (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, NMDA receptor antagonists, major depressive disorder, bipolar depression, treatment-resistant depression, rapid antidepressant effects, synaptic plasticity, brain-derived neurotrophic factor, mTOR, glycogen synthase kinase-3, treatment response biomarkers, antidepressant treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.